The findings suggest that C22orf2 transcriptional downmodulation in more differentiated hematopoietic progenitors of CML-CP has a marginal impact on Cby1 protein expression, whose levels are probably regulated by complementary events affecting the protein stability. The gene discussed is CBY1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.